Tirosine Kinase Inhibitors (TKI) Used in the Treatment of Non-Small Cell Lung Cancer (NSCLC) Based on Specific Genetic Alterations | Chapter 7 | Medical Science: Trends and Innovations Vol. 4

This review aims to describe the main TKI inhibitor therapeutic agents used in targeted therapy of non-small cell lung cancer (NSCLC). Thus, we described: Osimertinib, Erlotinib, Gefitinib, Afatinib, Dacomitinib, Alectinib, Brigatinib, Lorlatinib, Crizotinib. Some observations were made on Entrectinib, although there is no experience in its use, among the molecular determinations approved for reimbursement in Romania is the determination of NTRK fusion, for which Entrectinib is recommended. A similar situation is with Dacomitinib. The side effects of these compounds that sometimes limit their use were briefly presented. Aspects relevant to clinical practice and no basic research nor pipeline research were briefly presented. In conclusion, it is demonstrated that for patients who have the appropriate mutations, deletions or gene fusions TKI represent an important role in the personalized therapy of patients with NSCLC.

 

Author (s) Details

Alexandru Calin Grigorescu
Compartment of Medical Oncology, Clinical Hospital for Nephrology “Dr Carol Davila”, Calea Grivitei Nr4, Bucharest, Romania.

Please see the book here:- https://doi.org/10.9734/bpi/msti/v4/4098

Biomarkers for Early Detection of Lung Cancer | Chapter 7 | Research Developments in Medicine and Medical Science Vol. 3

 Lung Cancer is individual of the leading causes for tumor related deaths accompanying a 5-year continuation rate of only 18%.These are broadly divided into 2 types: NSCLC (non-limited cell alveolus cancer) and SCLC (small container lung tumor) and although treatments like a destructive agent, targeted situations are commonly used, the endurance rate is still very poor on account of the late detection of these cancers. Biomarkers are easily occurring biological genes that show changes when a tumor composition takes place. Various experimental and research data was brought back from search engines like PubMed, Google Scholar etc. Our item provides an overview of body part cancer, allure therapies, and mainly concentrates on potential biomarkers that take care of aid in the early detection of bronchi cancer.

Author(s) Details:

Vinit Vaidya,
Department of Botany, Thakur College of Science and Commerce, Thakur Village, Kandivali (East), Mumbai-400101, India.

Vedaant Bhandary,
Department of Botany, Thakur College of Science and Commerce, Thakur Village, Kandivali (East), Mumbai-400101, India.

Priyanshi Vishwakarma,
Department of Botany, Thakur College of Science and Commerce, Thakur Village, Kandivali (East), Mumbai-400101, India.

Faisal Qureshi,
Department of Botany, Thakur College of Science and Commerce, Thakur Village, Kandivali (East), Mumbai-400101, India.

Please see the link here: https://stm.bookpi.org/RDMMS-V3/article/view/9916

Bone Marrow Involvement in Non-Small Cell Lung Cancer | Chapter 7 | Highlights on Medicine and Medical Science Vol. 17

 Disseminated tumour cells (DTCs) in the bone marrow (BM) have been found to be distant metastasis progenitors. The finding of DTCs in non-small cell lung cancer (NSCLC) will provide critical information on metastatic characteristics, as well as the possibility of uncovering new targets for NSCLC treatment. The study's purpose is to examine if DTC can be found in BM and to figure out how often BM involvement is in NSCLC patients, as well as how it affects the lymphocyte population in the BM. 62 bone marrow samples from NSCLC patients were examined using morphological and immunological methods. Flow cytometry (FACS Canto II, USA, Kaluza Analysis v2.1 software) was used to analyse DTCs. Monoclonal antibodies to CD45, EPCAM, CD133, lymphocyte populations CD3, CD4, CD8, CD19, CD20, CD16, and CD27 were directly labelled with various fluorochromes. In 43.5 percent of patients, EPCAM+CD45- (DTCs) were identified in the BM (threshold level: 1 cell per 10 million myelocaricytes). In 33.3% (9/27) of the instances, CD133+EPCAM+CD45-cells were discovered. DTC presence had no correlation with tumour size, lymph node status, or tumour stage. Stages IA and IIA had the highest rates of DTC detection: 60.7 percent and 58.3 percent, respectively. BM involvement was observed in 45 percent of instances of adenocarcinoma and 37 percent of samples of squamous cell carcinoma (p = 0.501). Highly differentiated tumours had a higher prevalence of DTCs (p = 0.023). There are no significant links between the presence of DTCs in the BM and the parameters of the myelogram. In 4 percent of BM involvement, the number of granulocytic lineage cells decreased (p = 0.036). With BM injury, the level of CD16 + CD4-NK-cells (p = 0.002) and CD27 + CD3 + T-cells (p = 0.015) subpopulations increased significantly. DTCs can be found in the BM of NSCLC patients, according to the findings. The BM accounted for 43.5 percent of the participants. DTCs are observed even in the early stages of NSCLC. A relationship between BM involvement and the degree of tumour differentiation was established. Squamous cell lung cancer exhibited a higher rate of BM involvement than adenocarcinoma of the lung. The link between DTCs and BM lymphocyte populations was discovered: CD16 + CD4-, CD27 + CD3+ subpopulations.

Author (S) Details

Stilidi Ivan
Federal State Budgetary Institute “N.N. Blokhin National medical research center of oncology” of the Russian Ministry of Health, Moscow; Kashyrskoe sh.24, Moscow, 115478, Russia and Pirogov N.I. Russian National Research Medical University of the Russian Ministry of Health, 1, Ostrovitianova st., Moscow, 117997, Russia.

Kononetz Pavel
Federal State Budgetary Institute “N.N. Blokhin National medical research center of oncology” of the Russian Ministry of Health, Moscow; Kashyrskoe sh.24, Moscow, 115478, Russia.

Chulkova Svetlana
Federal State Budgetary Institute “N.N. Blokhin National medical research center of oncology” of the Russian Ministry of Health, Moscow; Kashyrskoe sh.24, Moscow, 115478, Russia and Pirogov N.I. Russian National Research Medical University of the Russian Ministry of Health, 1, Ostrovitianova st., Moscow, 117997, Russia.

Tupitsyn Nikolay
Federal State Budgetary Institute “N.N. Blokhin National medical research center of oncology” of the Russian Ministry of Health, Moscow; Kashyrskoe sh.24, Moscow, 115478, Russia.

View Book :- https://stm.bookpi.org/HMMS-V17/article/view/2610